Spencer Stumpf

Washington University in St. Louis — United States

Medicine · Health Sciences

15h-index2.5kcitations27works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(13), COVID-19 Clinical Research Studies(8), Microbial Natural Products and Biosynthesis(6), Genomics and Phylogenetic Studies(4), Plant Pathogens and Fungal Diseases(4)

Publications27 total

Potent antiproliferative dimeric biaryl-cyclohexapeptides from Lentzea flaviverrucosa
Phytochemistry Letters·2025
Critical analysis of polycyclic tetramate macrolactam biosynthetic gene cluster phylogeny and functional diversity
Applied and Environmental Microbiology·2024· 9 citedOpen Access
Piperazate-Guided Isolation of Caveamides A and B, Cyclohexenylalanine-Containing Nonribosomal Peptides from a Cave Actinomycete
Organic Letters·2024· 5 citedOpen Access
Critical analysis of polycyclic tetramate macrolactam biosynthetic cluster phylogeny and functional diversity
2024· 1 citedOpen Access
SARS-CoV-2 uses CD4 to infect T helper lymphocytes
eLife·2023· 54 citedOpen Access
Author response: SARS-CoV-2 uses CD4 to infect T helper lymphocytes
2023Open Access
SARS-CoV-2 requires acidic pH to infect cells
Proceedings of the National Academy of Sciences·2022· 97 citedOpen Access
SARS-CoV-2 requires acidic pH to infect cells
2022· 7 citedOpen Access
Discovery of unusual dimeric piperazyl cyclopeptides encoded by a <i>Lentzea flaviverrucosa</i> DSM 44664 biosynthetic supercluster
Proceedings of the National Academy of Sciences·2022· 19 citedOpen Access
SARS-CoV-2 productively infects primary human immune system cells <i>in vitro</i> and in COVID-19 patients
Journal of Molecular Cell Biology·2022· 61 citedOpen Access
Defining the risk of SARS-CoV-2 variants on immune protection
Nature·2022· 178 citedOpen Access
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Nature·2021· 565 citedOpen Access
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Nature·2021· 260 citedOpen Access
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
2021· 31 citedOpen Access
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Cell Host & Microbe·2021· 841 citedOpen Access
Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
2020· 111 citedOpen Access
SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes
2020· 42 citedOpen Access
Foliar Chemical Protection Against <i>Pantoea ananatis</i> in Onion Is Negated by Thrips Feeding
Phytopathology·2020· 8 citedOpen Access
Landscape Analysis of Escape Variants Identifies SARS-CoV-2 Spike Mutations that Attenuate Monoclonal and Serum Antibody Neutralization
SSRN Electronic Journal·2020· 84 citedOpen Access
Construction of a new integrating vector from actinophage ϕOZJ and its use in multiplex <i>Streptomyces</i> transformation
Journal of Industrial Microbiology & Biotechnology·2019· 15 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Sean P. J. Whelan(12), Louis-Marie Bloyet(10), Zhuoming Liu(9), Joshua A. V. Blodgett(7), Laura A. VanBlargan(5), John M. Errico(5), Ali H. Ellebedy(5), Daved H. Fremont(5), Michael Diamond(5), Marjorie Cornejo Pontelli(5), Yunci Qi(5), Paul W. Rothlauf(4), Rita E. Chen(4), Pei‐Yong Shi(4), R. D. Gitaitis(4), Bhabesh Dutta(4), Flávio P. Veras(4), Thiago M. Cunha(4), John M. D’Alessandro(4), Haiyan Zhao(3)